Axalta Coating Systems is generating stable returns on the same capital employed, not compounding earnings. Underlying trends suggest it may not be a potential multi-bagger. High return seekers may find better opportunities elsewhere.
Axalta Coating Systems is undervalued, suggesting a good time to buy more AXTA stock. The prosperous future outlook isn't fully reflected in the current price. Consider other factors like balance sheet strength before investing.
Investors in Axalta Coating Systems are expecting robust future growth, thus the high P/E ratio. A serious risk of earnings deterioration isn't seen likely and hence, a significant fall in share price seems unlikely.
Axalta Coating Systems' high debt usage to boost its ROE is worrying due to associated risks. Despite a fair ROE, the elevated debt level lacks appeal.
Axalta Coating Systems, with steady ROCE levels, doesn't seem to be reinvesting, indicating it might be past its growth stage. This limited return trend might be why its stock only gained 18% in the last five years, hinting at limited future high growth potential.
Axalta's leadership regards Mary Zappone's appointment positively, citing her broad expertise in critical sectors to the company's growth. Her CEO and chemical engineer experience is anticipated to significantly complement the board's capabilities.
Increased insider investment in Axalta Coating Systems indicates optimism for its future. Despite higher purchase prices, this shows belief in the stock’s value. However, some risks like the 1 warning sign remain.
Optimism in the market for Axalta Coating Systems Ltd is seen with EPS growth and increased share price. The company's positive outlook is boosted by insider investments, but risks remain to be considered before investing.
艾仕得塗料系統股票討論區
5年來毛利率從33.9%下滑到29.1%,營業費用總體小幅減少。
2022年利息費用佔營業利潤的33%,利息壓力極大。
目前34倍市盈率缺乏足夠的成長數據支持。
專欄Today's pre-market stock movers: TWTR, UPS, HSBC, JBLU and more
• $Avadel Pharmaceuticals(AVDL.US)$ +36.1% (continued volatility)
• $Gamida Cell(GMDA.US)$ +20.57% (announces FDA clearance of investigational IND and removal of clinical hold for GDA-201)
• $Venator Materials(VNTR.US)$ +14.61% (VNTR receives $85 mln settlement from Tronox)
• $歐伊諾(OI.US)$ +10.9% (earnings report)
• $康寧(GLW.US)$ +9% (earnings report)
• $Arch Resources(ARCH.US)$ +7.2% (earnings report)
• $宣偉公司(SHW.US)$ +6.1% (ea...
暫無評論